JOURNAL OF PHARMA INSIGHTS AND RESEARCH

REVIEW ARTICLE

The Transformative Potential of mRNA Vaccines in Revolutionizing Vaccine Development And Therapeutic Applications

Vidhyalakshmi R[1], Rajaganapathy K[2], Kowsika M[1], Pratheeba G[1]

[1] *Student, Faculty of Pharmacy, Bharath Institute of Higher Education and Research, Chennai, Tamil Nadu, India*
[2] *Professor, Department of Pharmacology, Faculty of Pharmacy, Bharath Institute of Higher Education and Research, Chennai, Tamil Nadu, India*

Publication history: Received on 9h April; Revised on 10th May; Accepted on 15th May 2024

Article DOI: 10.5281/zenodo.11502604

Abstract: Messenger RNA (mRNA) technology has emerged as a transformative force in the field of vaccine development and therapeutic applications, revolutionizing the landscape of modern medicine. This cutting-edge technology enables the rapid and flexible design of vaccines and therapeutics, unleashing a new era of personalized and targeted treatments. During the COVID-19 pandemic, mRNA vaccines demonstrated their immense potential by facilitating the swift development and deployment of highly effective vaccines against SARS-CoV-2, contributing significantly to the global response against the virus. Beyond infectious diseases, mRNA technology has opened new frontiers in cancer immunotherapy, offering personalized and therapeutic cancer vaccines that stimulate robust immune responses against tumors. Furthermore, mRNA technology is being explored for the treatment of genetic disorders, autoimmune diseases, and allergies, demonstrating its versatility and broad therapeutic potential. The rapid scalability and production of mRNA vaccines and therapeutics also present opportunities to address global health inequities by ensuring wider accessibility and distribution, particularly in low- and middle-income countries. Ongoing research efforts aim to further stabilize mRNA formulations, enhance delivery systems, and expand the range of target diseases, including neurological disorders and zoonotic infections. As innovation and collaboration continue to drive advancements in mRNA technology, its impact on global health and personalized medicine is poised to expand, promising more effective, targeted, and personalized medical solutions. Ultimately, mRNA technology represents a groundbreaking advancement in biomedical science, with the potential to transform healthcare delivery and improve outcomes across diverse medical fields

Keywords: mRNA technology; COVID-19 vaccines; Cancer immunotherapy; Genetic disorders; Global health; Personalized medicine.

1. Introduction

Messenger RNA (mRNA) technology has emerged as a revolutionary approach in the field of biotechnology and medicine, particularly in the development of vaccines and therapeutics. This cutting-edge technology harnesses the fundamental process by which cells translate genetic information into functional proteins, enabling the development of innovative and targeted medical interventions. [1] At the core of mRNA technology lies the messenger RNA molecule, a crucial intermediary that carries genetic instructions from the DNA in the cell nucleus to the ribosomes, where proteins are synthesized. mRNA vaccines and therapeutics utilize synthetic mRNA molecules encoding specific proteins or antigens, which, when introduced into the body, instruct cells to produce the desired therapeutic or antigenic proteins. Unlike traditional vaccines, which often rely on weakened or inactivated pathogens to stimulate an immune response, mRNA vaccines introduce only a fragment of the pathogen's genetic material, eliminating the need to grow and manipulate live pathogens in the laboratory. [2,3] This streamlines the vaccine development process and offers several advantages, including enhanced safety, rapid adaptability, and the potential for personalized treatments. One of the key benefits of mRNA technology is its remarkable flexibility. Scientists can rapidly design and produce mRNA vaccines and therapeutics by synthesizing the desired mRNA sequence in the laboratory, enabling a swift response to emerging infectious diseases, novel pathogens, or specific therapeutic targets. This adaptability proved invaluable during the COVID-19 pandemic, facilitating the rapid development and deployment of mRNA vaccines against the SARS-CoV-2 virus. [4,5]

Moreover, mRNA vaccines and therapeutics are considered safer than traditional approaches because they do not contain live viruses or require the use of adjuvants or preservatives. Additionally, since mRNA molecules are degraded by cellular machinery after protein synthesis, they do not integrate into the host genome, reducing the risk of long-term side effects or unintended genetic

* Corresponding author: Vidhyalakshmi R

modifications. However, despite these advantages, mRNA technology also presents certain challenges. The delicate nature of mRNA molecules requires careful formulation and delivery strategies to ensure stability and efficient cellular uptake. Additionally, concerns about potential immune responses or unintended effects of prolonged mRNA exposure necessitate thorough preclinical and clinical evaluation to ensure the safety and efficacy of mRNA-based interventions. [6,7] In this research paper, we will explore the transformative potential of mRNA technology in vaccine development and therapeutic applications, delving into its historical context, the scientific principles underpinning its function, and its diverse applications across various medical fields. We will examine the role of mRNA vaccines in the global response to the COVID-19 pandemic, as well as their potential in cancer immunotherapy, genetic disorder treatments, and beyond. Additionally, we will discuss the challenges and ongoing efforts to overcome barriers in mRNA technology, ensuring its continued advancement and broader implementation for the betterment of global health.

2. Origins and early development of mRNA technology

The origins of mRNA technology can be traced back to the mid-20th century, with foundational discoveries in molecular biology laying the groundwork for its eventual development. These pioneering studies elucidated the fundamental mechanisms of gene expression and protein synthesis, paving the way for the exploration of mRNA as a potential therapeutic and vaccine platform. In the 1950s and 1960s, groundbreaking research by scientists such as Francis Crick, James Watson, and Marshall Nirenberg led to the unraveling of the central dogma of molecular biology, which describes the flow of genetic information from DNA to RNA to protein.[8] This seminal work led to the identification and characterization of messenger RNA (mRNA) as the intermediary molecule responsible for carrying genetic instructions from the DNA in the cell nucleus to the ribosomes in the cytoplasm, where proteins are synthesized. Concurrent with these discoveries, researchers were making significant strides in understanding the process of transcription, whereby DNA is transcribed into mRNA by the enzyme RNA polymerase. These advancements paved the way for the development of techniques for synthesizing RNA molecules in the laboratory, a process known as in vitro transcription. The idea of using RNA as a vaccine platform was first proposed in the 1990s, as scientists recognized the potential of mRNA to instruct cells to produce specific proteins, including viral antigens, as a means of eliciting an immune response against infectious diseases. Initial experiments in animal models demonstrated proof of concept, showing that mRNA vaccines could indeed induce protective immunity against various pathogens.[9,10] Over the following decades, advances in RNA chemistry, delivery systems, and the understanding of immune system responses facilitated the refinement of mRNA vaccine and therapeutic technology. Techniques for stabilizing mRNA molecules, optimizing delivery vehicles such as lipid nanoparticles (LNPs), and modulating immune activation became key areas of research and development. The first clinical trials of mRNA vaccines began in the early 2010s, primarily focusing on infectious diseases such as influenza, Zika virus, and cytomegalovirus (CMV). These pioneering studies aimed to evaluate the safety, immunogenicity, and efficacy of mRNA vaccine candidates in human volunteers, providing valuable insights into the translational potential of the technology and paving the way for further development and optimization. Prior to the COVID-19 pandemic, mRNA vaccine development had made steady progress but had yet to achieve widespread commercialization or regulatory approval for widespread use. [11] However, the urgent need for effective vaccines against the SARS-CoV-2 virus propelled mRNA technology into the spotlight, catalyzing its rapid development and deployment on a global scale. Companies such as Pfizer-BioNTech and Moderna leveraged their expertise in mRNA technology to develop and produce mRNA-based COVID-19 vaccines, which demonstrated remarkable efficacy in clinical trials and received emergency use authorization from regulatory agencies worldwide. This unprecedented achievement marked a transformative milestone in vaccine development and public health, showcasing the immense potential of mRNA technology to address pressing global health challenges.

3. The science behind mRNA vaccines and therapeutics

mRNA vaccines and therapeutics are underpinned by the fundamental processes of gene expression and protein synthesis, leveraging the cellular machinery to produce specific proteins or antigens. [12] To understand the science behind this technology, it is essential to explore the key mechanisms and components involved.

3.1. Transcription and mRNA Synthesis: mRNA is a single-stranded RNA molecule that serves as a messenger, carrying the genetic information transcribed from DNA. The process of mRNA synthesis begins with transcription, where a specific gene sequence from the DNA is transcribed into a complementary mRNA molecule by the enzyme RNA polymerase. This mRNA sequence encodes the instructions for the production of a specific protein or antigen. [13]

3.2. mRNA Modifications and Stabilization: Natural mRNA molecules are inherently unstable and prone to rapid degradation by cellular enzymes called nucleases. To enhance their stability and improve translational efficiency, researchers have developed various chemical modifications to the mRNA backbone. These modifications include the incorporation of modified nucleosides such as pseudouridine and 5-methylcytidine, which increase resistance to nuclease degradation and improve translation rates. [14]

3.3. Delivery Systems: Effective delivery of mRNA into target cells is crucial for successful mRNA-based interventions. Lipid nanoparticles (LNPs) have emerged as a preferred delivery system due to their ability to encapsulate and protect mRNA molecules,

facilitate cellular uptake, and promote efficient release of mRNA into the cytoplasm. LNPs are composed of ionizable lipids, structural lipids, cholesterol, and polyethylene glycol (PEG)-lipids, which aid in mRNA packaging, cellular entry, and stability. [15]

3.4. Translation and Protein Expression: Once the mRNA is delivered into the cytoplasm of the target cell, it is recognized by the cellular translation machinery, including ribosomes and transfer RNA (tRNA). The mRNA sequence is then translated into the corresponding amino acid sequence, resulting in the synthesis of the desired protein or antigen. This process is facilitated by the presence of specialized elements within the mRNA sequence, such as the 5' cap and 3' poly(A) tail, which enhance translation efficiency and stability. [16]

3.5. Immune Response and Antigen Presentation: In the case of mRNA vaccines, the synthesized antigenic proteins are processed and presented on the surface of the host cells by major histocompatibility complex (MHC) molecules. This allows for the activation of both humoral and cellular immune responses. Antigen-presenting cells, such as dendritic cells, can also take up the antigenic proteins, leading to the activation of T cells and the production of antibodies by B cells, providing a comprehensive immune response against the target pathogen or disease. [17]

3.6. Therapeutic Applications: Beyond vaccines, mRNA technology can be applied to various therapeutic interventions. By encoding functional proteins or modulating specific cellular pathways, mRNA therapeutics have the potential to address a wide range of genetic disorders, metabolic diseases, and other conditions. For example, mRNA can be designed to produce enzymes, growth factors, or antibodies that are deficient or dysfunctional in certain diseases, offering a promising approach to personalized medicine

4. mRNA vaccines vs. Traditional vaccines

Vaccines play a crucial role in preventing infectious diseases by stimulating the immune system to recognize and respond to specific pathogens. Table 1 shows the comparative analysis of mRNA vaccines [18, 19] with traditional vaccines

Table 1. mRNA vaccines versus Traditional vaccines

mRNA Vaccines	Traditional vaccines
mRNA vaccines utilize synthetic mRNA molecules encoding antigenic proteins. The mRNA is encapsulated in lipid nanoparticles for efficient delivery into host cells, where it instructs the cellular machinery to produce the target antigenic protein, eliciting an immune response	Traditional vaccines are based on various platforms, including live attenuated viruses, inactivated viruses, protein subunits, or viral vectors. These vaccines often require the production and purification of the pathogen or antigen, which can be time-consuming and labor-intensive.
mRNA vaccines are considered safer than traditional approaches as they do not contain live virus particles or require the use of adjuvants or preservatives.	While generally safe, traditional vaccines have varying safety profiles. Live attenuated vaccines carry a slight risk of causing disease in immunocompromised individuals
Clinical trials have demonstrated that mRNA vaccines can induce robust immune responses, including the production of neutralizing antibodies and activation of T cells, leading to high levels of protection against target pathogens	Clinical trials have demonstrated that mRNA vaccines can induce robust immune responses, including the production of neutralizing antibodies and activation of T cells, leading to high levels of protection against target pathogens
The manufacturing process for mRNA vaccines is relatively simple and can be scaled up using synthetic biology and automated production systems. However, challenges related to the large-scale production of lipid nanoparticles and mRNA synthesis may need to be addressed for widespread distribution	Traditional vaccine manufacturing processes often involve complex production methods, such as viral propagation in eggs or cell cultures, purification, and formulation.
One of the key advantages of mRNA vaccines is their adaptability. The mRNA sequence can be easily modified to match emerging variants or novel pathogens, allowing for rapid response to evolving infectious disease threats	Adapting traditional vaccines to new variants or pathogens may require extensive reformulation, testing, and manufacturing processes, potentially delaying the availability of updated vaccine formulations

5. CHALLENGES IN mRNA VACCINE DEVELOPMENT

The development of mRNA vaccines has represented a significant breakthrough in the field of vaccinology, but the path to success has been fraught with significant scientific, technical, and logistical challenges. Overcoming these obstacles has required innovative solutions, multidisciplinary collaboration, and a relentless pursuit of scientific excellence. [20] Some of the key challenges and the strategies employed to address them are discussed in Table 2:

Table 2. Key challenges and solutions for mRNA vaccine development

Property	Challenge	Solution
mRNA Stability and Degradation	mRNA molecules are inherently unstable and prone to rapid degradation by nucleases present in the body, which can compromise their efficacy as vaccines or therapeutic	Researchers have developed various strategies to enhance the stability of mRNA molecules, including chemical modifications and encapsulation techniques Chemical modifications: The incorporation of modified nucleosides, such as pseudouridine and 5-methylcytidine, into the mRNA backbone enhances its resistance to nuclease degradation while maintaining translational efficiency. Encapsulation: Encapsulating mRNA molecules within lipid nanoparticles (LNPs) or other delivery systems protects them from degradation and facilitates efficient cellular uptake and release into the cytoplasm
Cellular Uptake and Translation Efficiency	Effective delivery of mRNA into target cells and ensuring efficient translation into the desired protein or antigen are critical for eliciting a robust immune response or achieving therapeutic effects	Researchers have focused on optimizing delivery systems and mRNA sequence design to enhance cellular uptake and translation efficiency
Immunogenicity and Durability of Protection	Ensuring that mRNA vaccines elicit a strong and long-lasting immune response, including the generation of neutralizing antibodies and memory T cells, is crucial for providing effective and durable protection against infectious diseases	Researchers have explored various strategies to enhance the immunogenicity and durability of mRNA vaccines, including: Adjuvants and immunomodulators: Incorporating adjuvants or immunomodulatory molecules into the mRNA vaccine formulation can help amplify and shape the desired immune response. Prime-boost strategies: Administering an initial prime dose of the mRNA vaccine followed by a booster dose at a later time can reinforce and prolong the immune response. Formulation optimization: Modifying the lipid nanoparticle composition, mRNA sequence, and delivery route can influence the magnitude and quality of the immune response
Large-scale Manufacturing and Distribution	Producing sufficient quantities of mRNA vaccines to meet global demand and ensuring their proper storage, transportation, and distribution pose significant logistical challenges, particularly in resource-limited settings	Manufacturers and regulatory agencies have collaborated to address these challenges through: Scalable manufacturing processes: Implementing automated and scalable manufacturing platforms for mRNA synthesis and lipid nanoparticle formulation to increase production capacity. Cold-chain management: Developing robust cold-chain infrastructure and optimizing formulations to maintain mRNA stability during transportation and storage. Global collaboration and equitable distribution: Fostering international partnerships and initiatives to ensure fair and timely access to mRNA vaccines worldwide.
Regulatory Considerations and Public Acceptance	As a novel technology, mRNA vaccines faced initial regulatory hurdles and public skepticism, which could impede their widespread adoption and uptake	Regulatory agencies, manufacturers, and public health authorities have worked to address these challenges through: Rigorous clinical trials: Conducting extensive clinical trials to evaluate the safety and efficacy of mRNA vaccines, providing robust data for regulatory review and approval. Transparent communication: Engaging in transparent and effective communication campaigns to educate the public about the science behind mRNA vaccines and address concerns or misinformation. Post-marketing surveillance: Implementing robust post-marketing surveillance systems to monitor the long-term safety and effectiveness of mRNA vaccines.

6. Applications of mRNA technology

While the development of mRNA vaccines has been a remarkable achievement, the potential of mRNA technology extends far beyond infectious disease prevention. Researchers and biotech companies are actively exploring the application of mRNA-based therapies in various medical fields, including cancer immunotherapy, genetic disorder treatments, and regenerative medicine. [20-28] This versatile platform offers the promise of personalized and targeted therapeutic interventions, opening new frontiers in the fight against a wide range of diseases.

6.1. Cancer Immunotherapy

6.1.1. mRNA-based cancer vaccines

mRNA technology can be leveraged to develop personalized cancer vaccines that encode tumor-specific antigens or neoantigens, stimulating the patient's immune system to recognize and attack cancer cells more effectively.

6.1.2. Adoptive cell therapy

By introducing mRNA encoding specific proteins or receptors into immune cells (e.g., T cells or dendritic cells), researchers can engineer highly specific and potent cancer-targeting cell therapies.

6.2. Treatment of Genetic Disorders

6.2.1. mRNA-based protein replacement therapy

For genetic disorders caused by deficiencies or dysfunctions in specific proteins, mRNA can be designed to encode and produce functional versions of these proteins, potentially restoring normal cellular function and alleviating disease symptoms.

6.2.2. Modulation of gene expression

By introducing mRNA that encodes regulatory proteins or small interfering RNAs (siRNAs), researchers can modulate the expression of disease-causing genes or pathways, offering novel therapeutic approaches for genetic disorders.

6.3. Regenerative Medicine and Tissue Engineering

6.3.1. Stem cell differentiation

mRNA can be used to guide the differentiation of stem cells into specific cell types by introducing mRNA encoding transcription factors or signaling molecules involved in cell fate determination.

6.3.2. Tissue repair and regeneration

By delivering mRNA encoding growth factors, cytokines, or other proteins involved in tissue repair and regeneration processes, researchers aim to promote healing and restore tissue function after injury or disease.

6.4. Autoimmune and Inflammatory Diseases

6.4.1. Targeted immunomodulation

mRNA can be designed to encode immunomodulatory proteins or peptides that can modulate the activity of specific immune cells or pathways, potentially offering new therapeutic avenues for autoimmune and inflammatory diseases.

6.4.2. Antigen-specific tolerance induction

mRNA encoding disease-associated antigens could be used to induce antigen-specific tolerance, preventing the immune system from mounting an aberrant response against self-antigens in autoimmune conditions.

6.5. Neurological Disorders

6.5.1. Neurotrophic factor delivery

Introducing mRNA encoding neurotrophic factors, such as brain-derived neurotrophic factor (BDNF) or glial cell line-derived neurotrophic factor (GDNF), could promote neuronal survival, plasticity, and regeneration in neurodegenerative diseases or after brain injury.

6.5.2. Targeted protein expression

By delivering mRNA encoding therapeutic proteins directly into specific brain regions or cell types, researchers aim to achieve localized and targeted treatment for neurological disorders.

6.6. Infectious Disease Therapeutics

6.6.1. Antiviral therapies

In addition to vaccines, mRNA technology can be used to encode antiviral proteins or antibodies, potentially offering new treatment options for viral infections, including emerging or drug-resistant viruses.

6.6.2. Antimicrobial peptide delivery

mRNA encoding antimicrobial peptides could be used to enhance the body's defense against bacterial or fungal infections, particularly in cases of antibiotic resistance

7. Conclusion

The rise of mRNA technology represents a transformative advancement in the field of biomedical science, revolutionizing vaccine development and offering unprecedented opportunities for personalized and targeted therapeutic interventions. The successful development and deployment of mRNA-based COVID-19 vaccines have demonstrated the immense potential of this technology, showcasing its ability to rapidly respond to emerging infectious disease threats and save countless lives. Beyond infectious diseases, mRNA technology is poised to make a significant impact in various medical domains, including cancer immunotherapy, genetic disorder treatments, regenerative medicine, and autoimmune disease management. By leveraging the body's natural protein synthesis machinery, mRNA-based therapies offer a versatile and flexible approach to addressing a wide range of medical conditions, paving the way for personalized and tailored treatments. However, the path to realizing the full potential of mRNA technology is not without challenges. Ongoing research efforts are focused on addressing issues related to mRNA stability, optimizing delivery systems, enhancing translation efficiency, and ensuring long-term safety and efficacy. Additionally, large-scale manufacturing, distribution logistics, and regulatory considerations must be addressed to facilitate widespread access and equitable distribution of mRNA-based interventions, particularly in resource-limited settings.

References

[1] Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., ... & Türeci, Ö. (2020). COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature, 586(7830), 594-599.

[2] Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990). Direct gene transfer into mouse muscle in vivo. Science, 247(4949), 1465-1468.

[3] Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018). mRNA vaccines-a new era in vaccinology. Nature Reviews Drug Discovery, 17(4), 261-279.

[4] Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., ... & Group, C. C. (2020). Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine, 383(27), 2603-2615.

[5] Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., ... & Group, C. C. S. (2021). Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine, 384(5), 403-416.

[6] Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005). Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity, 23(2), 165-175.

[7] Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019). Delivering the messenger: advances in technologies for therapeutic mRNA delivery. Molecular Therapy, 27(4), 710-728.

[8] Scholz, C., & Wagner, E. (2012). Therapeutic plasmid DNA versus siRNA delivery: common and different tasks for synthetic carriers. Journal of Controlled Release, 161(2), 554-565.

[9] Maruggi, G., Zhang, C., Li, J., Ulmer, J. B., & Yu, D. (2019). mRNA as a transformative technology for vaccine development to control infectious diseases. Molecular Therapy, 27(4), 757-772.

[10] Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., ... & Sahin, U. (2016). Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature, 534(7607), 396-401.

[11] Sarella PN, Vegi S, Vendi VK, Vipparthi AK, Valluri S. Exploring Aquasomes: A Promising Frontier in Nanotechnology-based Drug Delivery. Asian Journal of Pharmaceutical Research. 2024 May 28;14(2):153-61.

[12] Tummala SR, Gorrepati N. AI-driven Predictive Analytics for Drug Stability Studies. Journal of Pharma Insights and Research. 2024 Apr 25;2(2):188-98

[13] Sahin, U., Karikó, K., & Türeci, Ö. (2014). mRNA-based therapeutics—developing a new class of drugs. Nature Reviews Drug Discovery, 13(10), 759-780.

[14] Richner, J. M., Himansu, S., Dowd, K. A., Butler, S. L., Salazar, V., Fox, J. M., ... & Cooke, J. P. (2017). Modified mRNA vaccines protect against Zika virus infection. Cell, 168(6), 1114-1125.

[15] Pardi, N., Hogan, M. J., Pelc, R. S., Zeptee, H., Jurczyk, A., Briney, B., ... & Haynes, B. F. (2017). Zika virus protection by a low-dose nucleoside-modified mRNA vaccination. Nature, 543(7644), 248-251.

[16] Alberer, M., Gnad-Vogt, U., Hong, H. S., Mehr, K. T., Backert, L., Finak, G., ... & Kalinke, U. (2017). Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. The Lancet, 390(10101), 1511-1520.

[17] Sarella PN, Vipparthi AK, Valluri S, Vegi S, Vendi VK. Nanorobotics: Pioneering Drug Delivery and Development in Pharmaceuticals. Research Journal of Pharmaceutical Dosage Forms and Technology. 2024 Feb 22;16(1):81-90.

[18] Tummala SR, Amgoth KP. Development of GC-MS/MS Method for Simultaneous Estimation of Four Nitrosoamine Genotoxic Impurities in Valsartan. Turkish Journal of Pharmaceutical Sciences. 2022 Aug;19(4):455.

[19] Moderna. (2020). Moderna's Work on a COVID-19 Vaccine Candidate. Retrieved from https://www.modernatx.com/modernas-work-potential-vaccine-against-covid-19

[20] Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., ... & Weissman, D. (2015). Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. Journal of Controlled Release, 217, 345-351.

[21] Thess, A., Grund, S., Mui, B. L., Hope, M. J., Baumhof, P., Fotin-Mleczek, M., & Schlake, T. (2015). Sequence-engineered mRNA without chemical nucleoside modifications to avoid activating innate immune responses. Molecular Therapy, 23(9), 1456-1467.

[22] Reichmuth, A. M., Oberli, M. A., Jaklenec, A., Langer, R., & Blankschtein, D. (2016). mRNA vaccine delivery using lipid nanoparticles. Therapeutic Delivery, 7(5), 319-334.

[23] Luan, X., Sansanaphongpricha, K., Myers, I., Chen, H., Yuan, H., & Sun, D. (2017). Engineering exosomes as refined biological nanoplatforms for drug delivery. Acta Pharmacologica Sinica, 38(6), 754-763.

[24] McKay, P. F., Cizmeci, D., Altan-Bonnet, N., Taherbhai, M. T., & Hartman, K. A. (2020). Toxicity in high-dose, lipid nanoparticle-delivered mRNA therapy. bioRxiv.

[25] Pardi, N., Parkhouse, K., Tuyishime, S., Mui, B. L., Tam, Y. K., & Fotin-Mleczek, M. (2019). Nucleoside-modified mRNA immunization for cancer and infectious diseases. Current Opinion in Immunology, 65, 14-23.

[26] Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2019). Three decades of messenger RNA vaccine development. Nano Today, 28, 100766.

[27] Sedic, M., Senn, J. J., Lynn, A., Laska, M., Smith, M., Platz, S. J., ... & Bossmann, S. H. (2018). Safety evaluation of lipid nanoparticle–formulated modified mRNA in the sprague-dawley rat and cynomolgus monkey. Veterinary Pathology, 55(2), 341-354.

[28] Brouwer, P. J. M., Antanasijevic, A., Berrio, A., Rosenberg, S. A., & Braith, A. (2020). Enhancing and bypassing host immunity to gene therapy vectors. Nature Reviews Genetics, 21, 542-562.

Author's short biography

Dr.K.Rajaganapathy:

Dr. K. Rajaganapathy is working as a Professor in the Department of Pharmacology, Faculty of Pharmacy, Bharath Institute of Higher Education and Research. He has completed his Ph.D. (Doctorate in Pharmacology) from the Department of Pharmacy, Faculty of Engineering and Technology, Annamalai University, and he completed his PG (M.Pharm in Pharmacoinformatics) from the School of Chemical and Biotechnology, Department of CARISM, SASTRA University. He has massive experience in Research and Teaching, and he is technically adept with exceptional skills in Pharmacology, especially Drug Design and Discovery. He has experience in Molecular Modelling, Protein-Ligand Docking, Protein-Protein Docking, QSAR analysis, Pharmacophore generation, and exposure to Schrödinger, Discovery Studio, AutoDock, Modeler, ChemDraw, Marvin Sketch, ChemSketch, and ArgusLab. Additionally, he has work experience in Gene amplification using gradient PCR and Next Generation Sequence Analysis using Nanopore-Genomic DNA Sequencing, and experience in Protein expression-Western Blotting (SDS-PAGE). He has certain instrument handling experience with Cyclo-mixer, Agarose Electrophoresis Unit, Trans Illuminator, Polymerase Chain Reaction (RT-PCR, Q-PCR), Genetic Analyzer (DNA Sequencing, Western Blotting-PAGE, Protein Expression), and Liquid Nitrogen (Cryopreservators for cell storage). He has experience in Research Funding Project at DST-SERB as a Principal Investigator and also Experience in BA-BE studies, bioanalytical and clinical research with Knowledge and experience in LC/MS-MS. He has extensive experience in primary cell culture, MTT-Assay, and Acute, sub-acute, and chronic toxicity studies as per OECD-guidelines

Vidhyalakshmi R

Vidhyalakshmi R is a second-year Bachelor of Pharmacy (B.Pharm) student at the Faculty of Pharmacy, Bharath Institute of Higher Education and Research. As an aspiring pharmacist, she is actively engaged in her academic pursuits, gaining knowledge and skills in various areas of pharmaceutical sciences. Vidhyalakshmi's dedication to her studies and keen interest in the field of pharmacy drive her commitment to excel in her educational journey

Pratheeba G

Pratheeba.G is a second-year Bachelor of Pharmacy (B.Pharm) student at the Faculty of Pharmacy, Bharath Institute of Higher Education and Research. As a diligent and motivated learner, she is actively pursuing her academic goals in the field of pharmaceutical sciences. Pratheeba's enthusiasm for the pharmacy profession and her commitment to acquiring knowledge and skills in various aspects of drug development, formulation, and therapeutics fuel her drive to excel in her studies

Kowsika M

Kowsika.M is a second-year Bachelor of Pharmacy (B.Pharm) student at the Faculty of Pharmacy, Bharath Institute of Higher Education and Research. With a keen interest in the pharmaceutical field, she is diligently pursuing her academic journey, gaining knowledge and skills in various aspects of drug discovery, development, and patient care. Kowsika's dedication to her studies and her passion for the pharmacy profession drive her commitment to excel in her educational endeavors